The inhibition of sertraline-induced serotonin syndrome by inadvertent co-ingestion of risperidone in a suicidal attempt: a case report
Main Article Content
Abstract
BACKGROUND: Suicidal thoughts and attempts are commonly observed among patients with depression. The presence of concomitant psychotic symptoms in a patient with an existing depression increases the risk of drug-drug interactions, especially in cases when multiple drugs are used for treatment.
CASE PRESENTATION: This case report describes a young adult female with a history of psychosis and depression, for which she had been taking risperidone and sertraline for the past six months. She was brought to the hospital by her family members after an alleged suicide attempt using her psychiatric medications. On examination, the patient exhibited disturbed consciousness and a moderately elevated body temperature, but notably, no muscle rigidity.
These clinical features suggested a mild form of serotonin syndrome (SS). Despite a 1500 mg sertraline overdose, which would typically result in symptoms such as severe agitation, hallucinations, sweating, flushing, or tremors, the patient's SS was unexpectedly mild considering the amount of drugs ingested.
CONCLUSION: It was concluded that the patient developed serotonin syndrome (SS) due to a toxic overdose of sertraline. However, the severity of SS was mitigated by the concurrent ingestion of an equivalent dose of risperidone, a serotonin receptor antagonist. As a result, the condition was classified as mild to moderate SS, which, despite the large dose of the selective serotonin reuptake inhibitor, did not necessitate the use of an antidote.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Work published in KMUJ is licensed under a
Creative Commons Attribution 4.0 License
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
References
1. Turner AH, Nguyen C, Kim J, McCarron R. Differentiating serotonin syndrome and neuroleptic malignant syndrome. Curr Psychiatr 2019;18:30-6.
2. Duignan KM, Quinn AM, Matson AM. Serotonin syndrome from sertraline monotherapy. Am J Emerg Med 2020;38(8):1695.e5-e6. https://doi.org/10.1016/j.ajem.2019.158487
3. Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J 2013;13(4):533-40.
4. Chandrasekaran P, Grewal G. An Approach to Diagnosing and Managing Neuroleptic Malignant Syndrome, Atypical Neuroleptic Malignant Syndrome, and Serotonin Syndrome using a Flowchart Algorithm. Austin J Pharmacol Ther 2015;3(2):1072. https://doi.org/10.1080/10673220701551110
5. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ 2014;348. https://doi.org/10.1136/bmj.g1626